WATCH THE FREE ON-DEMAND WEBINAR: Watch on Phacilitate
LEARN MORE ABOUT THE PROMISING RESULTS OF THE KYTOPEN EARLY-ACCESS PROGRAM IN THE HANDS OF DRUG DEVELOPERS AND THE IMPACT OF THE NEWEST GENOME ENGINEERING TOOL.
Are you looking to improve your genome engineering processes by simplifying and accelerating your payload delivery? Discover how drug researchers, CDMOs, and biotech companies are utilizing Flowfect® to streamline and scale their payload delivery.
Although cell and gene therapy holds great promise for patients, manufacturing is time-consuming and expensive. One of the greatest challenges is the effective delivery of payloads to cells.
Currently, the predominant method of non-viral transfection used to deliver various nucleic acid and protein payloads, such as DNA, mRNA, and CRISPR-Cas RNPs, to cells is via electrical disruption of cellular membranes. However, these methods do not scale from initial discovery through process optimization to manufacturing scale.
The Flowfect® solution provides an electro-mechanical transfection, realized in high throughput and large volume configurations, to remove therapeutic research and production barriers. With Flowfect®, you can accelerate therapies from the bench to clinical applications, driving higher cell yields, shorter development and manufacturing times, and better outcomes from potentially curative cell-based medicines.
Join Kytopen and a panel of experts to discuss challenges related to payload delivery and the impact of new tools on drug discovery and manufacturing. The panel of experts will also share their results using new Flowfect® platforms for delivering complex genome engineering components to living medicines.
WHAT TO EXPECT
Part 1: Introduction – meet the technology and meet the collaborators:
- Introduction to Flowfect® and Engineering Tomorrow’s Medicine – Bethany Grant, Kytopen CTO
- Collaborator presentations
Part 2: Panel discussion, considering questions including:
- What are the benefits of using viral vs non-viral delivery for payloads (such as mRNA, DNA, Plasmids, RNP) to cells used in cell therapies?
- What are the greatest challenges regarding non-viral delivery, and how do developers mitigate these challenges?
- What are the limiting bottlenecks to process development and scaling therapies from the discovery stage to the manufacturing stage?
- The next generation of therapeutics will consist of highly variable payloads; what is the future of gene editing tools and payloads, and what is limiting the factor for making this a reality today?
Part 3: The panel answers audience questions with an interactive Q&A.
MEET THE PANEL